ARA 290 16mg

ARA 290 16mg

$104.00

ARA-290 is a synthetic 11-amino acid peptide derived from the structural framework of erythropoietin (EPO), specifically designed to trigger the innate repair receptor (IRR). Unlike traditional EPO, ARA-290 delivers tissue-protective and regenerative benefits without stimulating red blood cell production. With a molecular weight of 1257 daltons, this peptide mimics the spatial arrangement of EPO’s B-helix, making it highly effective in promoting tissue repair, reducing neuropathic pain, and enhancing metabolic control, as demonstrated in both preclinical and clinical research.

Category:

Description

Referenced Citations

  1. Brines, M., et al. (2014). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine, 20(1), 658-666. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365069/
  2. Heij, L., et al. (2012). Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study. Molecular Medicine, 18, 1430–1436. [Online].
    Available https://molmed.biomedcentral.com/articles/10.2119/molmed.2012.00332
  3. Dahan, A., et al. (2016). Targeting the innate repair receptor to treat neuropathy. Pain Reports, 1(1), e566. [Online].
    Available: https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx
  4. Lois, N., et al. (2020). A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of Clinical Medicine, 9(7), 2225. [Online].
    Available: https://www.mdpi.com/2077-0383/9/7/2225
  5. Brines, M., et al. (2014). ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Molecular Medicine, 20(1), 658-666. [Online]. .
    Available: https://molmed.biomedcentral.com/articles/10.2119/molmed.2014.00215
  6. Dahan, A., et al. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine, 19(1), 334-345. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883966/

Related products